BitranJ. D., DesserR. K., BillingsA. A.: Acute nephrotoxicity following cis-dichlorodiammineplatinum. Cancer, 49; 1784 (1982).
2.
CarraraM., MantovaniG., CimaL.: Modalità e prospettive per la prevenzione degli effetti tossici del Cisplatino. Argomenti Oncol., 7; 27 (1986).
3.
CitrinD. L., CohenA. I., HarbertJ.: Systemic treatment of advanced prostate cancer: development of a new system for defining response. J. Urol., 125; 224 (1981).
4.
CitrinD. L., HoganT. F.: A phase II evaluation of Adriamycin and Cis-platinum in hormone resistant prostate cancer. Cancer, 50; 201 (1982).
5.
CrookeS. T., CarterS. K. (eds.): Cisplatin. Academic Press Inc., New York 1980.
6.
HayesD. M., CvitkovicE., GolbeyR. B.: High dose cisplatinum-diammine-dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer, 39; 1372 (1977).
7.
LoeninS. A., BeckleyS., BradyM. F.: Comparison of Estramustine phosphate, Methotrexate and Cis-platinum in patients with advanced, hormone refractory prostate cancer. J. Urol., 129; 1001 (1983).
8.
MarchJ.L.N.: Evaluation of the efficacy of cis-platinum in the treatment of disseminated prostatic cancer. Arch. Esp. Urol., 38; 28 (1985).
9.
MariniF., SignoriG. B., PeregoS.: Il trattamento del carcinoma prostatico allo stadio avanzato con Cis-diamminodicloroplatino. Urologia, 47; 138 (1980).
10.
MerrinC.: Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J. Urol., 119; 522 (1978).
11.
MerrinC. E., BeckleyS.: The treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diamminedichloroplatinum. Urology, 13; 267 (1979).
12.
PastorelloM., BorelliC., CasolariE.: Terapia medica del carcinoma prostatico in stadio D: Cis-platinum. Atti Soc. Ital. Urol., 56° Congr., p. 363, Verona 1983.
13.
P.O.N.CA.P.: Il carcinoma della prostata. GiulianiL., SantiL. (eds.), Genova 1985.
14.
RosenbergB., van CampL., KirgesT.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205; 698 (1965).
15.
RosenbergB., vanCamp L., TroskoJ.: Platinum compounds: a new class of potent antitumor agents. Nature, 222; 385 (1969).
16.
SlackN. H., MittelmanA., BradyM. F.: The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer, 46; 2393 (1980).
17.
SlackN. H., BradyM. F., MurphyG.P.: A re-examination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer, 54; 564 (1984).
18.
SolowayM. S.: A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J. Urol., 129; 56 (1983).
19.
YagodaA., WatsonR. C., NataleR. B.: A critical analysis of response criteria in patients with prostatic cancer treated with cis-DDP. Cancer, 44; 1553 (1979).
